GlassScriptPhysician profile
Mohammad Alkotob
NPI 1598792830
$10,178.27
in general payments reported to CMS, 2019-2025
47 companies · $2,726 in 2025
The $2,726 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,807 · 2020: $587 · 2021: $954 · 2022: $1,122 · 2023: $1,270 · 2024: $713 · 2025: $2,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,733 · Travel and Lodging: $1,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,732.88 |
| Travel and Lodging | $1,977.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,221.65 | 2023-2025 | Symplicity G3, V-Loc 180 |
| Biotronik INC. | $1,609.07 | 2019-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Biomonitor |
| Novartis Pharmaceuticals Corporation | $1,109.80 | 2019-2025 | |
| Cardiovascular Systems INC. | $886.29 | 2019-2021 | |
| Amgen INC. | $626.66 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $427.60 | 2021-2025 | Verquvo |
| Pfizer INC. | $380.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $335.76 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $305.77 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $246.38 | 2019-2025 | Lifevest |
| Abiomed | $222.69 | 2023-2025 | Impella |
| Kestra Medical Technology Services, INC. | $189.70 | 2022-2025 | Assure Wcd |
| Inari Medical, INC. | $163.31 | 2019-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.52 | 2019-2023 | Jardiance |
| Cordis US Corp. | $112.25 | 2021-2025 | Mynxgrip, Mynx Control Venous, Infiniti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alkotob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.